 vein bypass graft patency,
although their use is still warranted to reduce future cardiovascular ischemic events and stroke. Patency may be
improved with antiplatelet therapy in patients undergoing
prosthetic bypass. The use of warfarin anticoagulation after
lower extremity bypass remains controversial, and signiÔ¨Åcant differences exist in its use between North American
and European vascular surgeons. In the United States, anticoagulation is used selectively in vein bypass procedures
with either